- News article -

Desensitization 2.0: Desentum develops a game changer for treating allergies

29 Oct 2018

Desentum has received 1,9 million euros of EU funding for their unique solution, a biotechnological vaccine for treating allergies. The first test case is birch pollen allergy but thanks to its mechanism, this platform technology is applicable to other allergies alike.

Allergy is a huge problem especially in the developed countries. Although it is seldom life-threatening, the sheer number of patients makes the condition a serious concern for societies. Globally, allergic diseases already affect one billion people and the number is increasing. Allergies restrict the lives of the patients, decrease productivity, cause missed work and school days and place economic burden to both individuals and societies.

Finnish biopharmaceutical company Desentum has received 1,9 MEUR funding from EU commission for developing their product, which can change the current practice of treating allergies. Spinverse helped Desentum in the exceptionally tough funding application process: Out of 1650 proposals only 4 %, or 66, received the funding.

Breakthrough technology

What was so convincing about the solution? University of Eastern Finland and VTT Technical Research Centre of Finland Ltd discovered that allergens form dimers (pairs) when binding to the molecular complex that triggers the allergic reaction. The breakthrough idea was to prevent this dimerization and thus the allergic reaction itself.

“We make targeted modifications to allergens to reduce their ability to trigger allergic reactions while retaining their 3D structure as close to natural allergens as possible. The goal is that when the modified allergens are used in allergen immunotherapy, i.e. desensitization, the reduced allergenicity allows us to use larger amounts of allergens, thus improving the efficacy of the treatment. The natural-like 3D structure makes sure that the induced protection works against the natural allergens and not just the vaccine molecules”, says Pekka Mattila, CEO of Desentum.

Quick desensitization

Not only can this solution improve lives of millions of people, but the business potential in this case is also clear: even though allergen immunotherapy currently only holds 1/10 of the allergy market, it is already a billion-euro business. The European Academy of Allergy and Clinical Immunology estimates that annual savings of 142 billion euros could be realized in EU alone if allergies were properly diagnosed and treated with current options. Novel therapies could benefit the society even more.

The benefit of Desentum’s solution is that desensitization process is significantly quicker and more efficient compared to the traditional desensitization practices, which can take up to five years, require a lot of commitment and are often not carried through.

After seven years of development in laboratory the project is now proceeding to clinical phase. The funding from EU commission will help Desentum run the first clinical trial and build partnerships for future commercialization of the technology.

Spinverse supported Desentum in project preparation, including help in defining the scope, business and commercialization potential as well as assisting in writing the proposal. After a positive decision from EU commission, Spinverse guided Desentum through the complex phase of signing the grant agreement with the European Commission.

“We are very proud that Spinverse helped Desentum in securing 1.9 M€ EU funding (Horizon 2020 SME Phase 2 instrument). However, that was only the first phase of our cooperation: Once the actual project starts in December 2018, Spinverse will be supporting Desentum with project management for the next three years. We are looking forward to seeing Desentum’s innovation turning into real business”, says Managing Director of Spinverse Laura Koponen.

See also:
Desentum’s press release

- Contact us -

Want to learn how Spinverse could help you? Contact us now!



Laura Koponen

Managing Director, D.Sc. (Tech.) +358 40 350 0898

- News -

Relevant posts

CTO Forum CTO of the Year CTO Survey

Cross-industry CTO Forum brings together Finnish technology leaders on 16th February

26 Jan 2021

The annual CTO Forum co-organised by Business Finland, Technology Industries of Finland and Spinverse is app...

Client News EU funding health technology

Project STARDUST aims to bring a new and revolutionary treatment approach for Parkinson’s patients

8 Jan 2021

Spinverse is one of the nine partners in the STARDUST project, launched in 2017, to create a miniaturised ne...

5G LuxTurrim5G

Smart Urban Furniture showcase offers a sneak peek into the future of cities

5 Jan 2021

In close collaboration with several LuxTurrim5G partners, the Aalto Design Factory (ADF) team has developed ...

CTO Forum CTO of the Year

Nominate your candidate for CTO of the Year 2021 and Innovation Professor of the Year 2021!

16 Dec 2020

Have you worked with an exceptional CTO in Finland? Would you also like to highlight an innovative professor...

health technology Our People CleverHealth Network

Talking about the future of health technologies with Heli Teerenhovi

14 Dec 2020

Heli Teerenhovi joined Spinverse as Senior Manager less than two months ago and has already familiarised her...

Client News digital healthcare H2020

Spinverse helped AICCELERATE get 10 M€ funding – project aims to develop AI solutions to improve hospital processes and patient care pathways

14 Dec 2020

The European Commission recently funded AICCELERATE, a multiparty project aiming to develop AI solutions to ...